TY - JOUR
T1 - Heparanase overexpression induces glucagon resistance and protects animals from chemically induced diabetes
AU - Zhang, Dahai
AU - Wang, Fulong
AU - Lal, Nathaniel
AU - Chiu, Amy Pei Ling
AU - Wan, Andrea
AU - Jia, Jocelyn
AU - Bierende, Denise
AU - Flibotte, Stephane
AU - Sinha, Sunita
AU - Asadi, Ali
AU - Hu, Xiaoke
AU - Taghizadeh, Farnaz
AU - Pulinilkunnil, Thomas
AU - Nislow, Corey
AU - Vlodavsky, Israel
AU - Johnson, James D.
AU - Kieffer, Timothy J.
AU - Hussein, Bahira
AU - Rodrigues, Brian
N1 - Funding Information:
This work was supported by an operating grant from the Canadian Institutes of Health Research (CIHR-MOP-133547 to B.R.). D.Z. and A.P.-L.C. are the recipients of Doctoral Student Research Awards from the Canadian Diabetes Association.
Publisher Copyright:
© 2017 by the American Diabetes Association.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Heparanase, a protein with enzymatic and nonenzymatic properties, contributes toward disease progression and prevention. In the current study, a fortuitous observation in transgenic mice globally overexpressing heparanase (heptg) was the discovery of improved glucose homeostasis. We examined the mechanisms that contribute toward this improved glucose metabolism. Heparanase overexpression was associated with enhanced glucose-stimulated insulin secretion and hyperglucagonemia, in addition to changes in islet composition and structure. Strikingly, the pancreatic islet transcriptome was greatly altered in hep-tg mice, with >2,000 genes differentially expressed versus control. The upregulated genes were enriched for diverse functions including cell death regulation, extracellularmatrix component synthesis, and pancreatic hormone production. The downregulated genes were tightly linked to regulation of the cell cycle. In response to multiple lowdose streptozotocin (STZ), hep-tg animals developed less severe hyperglycemia compared with wild-type, an effect likely related to their β-cells being more functionally efficient. In animals given a single high dose of STZ causing severe and rapid development of hyperglycemia related to the catastrophic loss of insulin, hep-tg mice continued to have significantly lower blood glucose. In these mice, protective pathways were uncovered for managing hyperglycemia and include augmentation of fibroblast growth factor 21 and glucagon-like peptide 1. This study uncovers the opportunity to use properties of heparanase in management of diabetes
AB - Heparanase, a protein with enzymatic and nonenzymatic properties, contributes toward disease progression and prevention. In the current study, a fortuitous observation in transgenic mice globally overexpressing heparanase (heptg) was the discovery of improved glucose homeostasis. We examined the mechanisms that contribute toward this improved glucose metabolism. Heparanase overexpression was associated with enhanced glucose-stimulated insulin secretion and hyperglucagonemia, in addition to changes in islet composition and structure. Strikingly, the pancreatic islet transcriptome was greatly altered in hep-tg mice, with >2,000 genes differentially expressed versus control. The upregulated genes were enriched for diverse functions including cell death regulation, extracellularmatrix component synthesis, and pancreatic hormone production. The downregulated genes were tightly linked to regulation of the cell cycle. In response to multiple lowdose streptozotocin (STZ), hep-tg animals developed less severe hyperglycemia compared with wild-type, an effect likely related to their β-cells being more functionally efficient. In animals given a single high dose of STZ causing severe and rapid development of hyperglycemia related to the catastrophic loss of insulin, hep-tg mice continued to have significantly lower blood glucose. In these mice, protective pathways were uncovered for managing hyperglycemia and include augmentation of fibroblast growth factor 21 and glucagon-like peptide 1. This study uncovers the opportunity to use properties of heparanase in management of diabetes
UR - http://www.scopus.com/inward/record.url?scp=85007300447&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007300447&partnerID=8YFLogxK
U2 - 10.2337/db16-0761
DO - 10.2337/db16-0761
M3 - Article
C2 - 27999107
AN - SCOPUS:85007300447
SN - 0012-1797
VL - 66
SP - 45
EP - 57
JO - Diabetes
JF - Diabetes
IS - 1
ER -